Skip to content

EOD 3.2

Latest
Latest
Compare
Choose a tag to compare
@ctmay4 ctmay4 released this 14 Aug 15:35
v11.3.0
190f391

EOD v3.2 Review and Conversion:

After EOD v3.2 has been deployed

  1. NET Appendix EOD Primary Tumor [772]: For code 200, the calculation of Derived EOD 2018 T [785] should not depend on the Tumor Size Summary [756] and has been adjusted. This affects Derived EOD 2018 T [785] and Derived EOD 2018 Stage Group [818] for both the 8th and V9 versions of NET Appendix.
    If your registry captures/calculates Derived EOD 2018 fields:

    • If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00320 (NET Appendix 8th) or 09320 (NET Appendix V9) and EOD Primary Tumor [772] = 200
      • Set Derived EOD 2018 T [785] = T3
      • If Derived EOD 2018 M [795]= M0
        • If Derived EOD 2018 N [815] = NX, then Set Derived EOD 2018 Stage Group [818] = 99
        • If Derived EOD 2018 N [815] = N0, then Set Derived EOD 2018 Stage Group [818] = 2
    • OR Recalculate the EOD Derived fields for Schema ID [3800] = 00320 or 09320
    • No other changes are necessary
    • (This can always be applied. Calculation tables were updated. No review necessary.)

  2. Appendix EOD Primary Tumor [772], EOD Mets [776]: Code 600 has been removed from EOD Primary Tumor [772] and cases with that code must have EOD Primary Tumor [772] and potentially EOD Mets [776] adjusted.
    If your registry captures the EOD 2018 fields:

    • If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00190 (Appendix 8th), 09190 (Appendix V9) and EOD Primary Tumor [772] = 600
      • Set EOD Primary Tumor [772] = 500
      • If EOD Mets [776] = 00, 10 then set EOD Mets [776] = 30
    • This should trigger the EOD derivations.
    • No other changes are necessary
    • (This can always be applied. Code 600 was not reused. No review necessary.)

EOD v3.2 changes:

EOD and SS2018 - includes changes to schema definitions, EOD fields and SS2018

  • General Changes

    • The structure of the notes was modified so the notes have a header in bold to improve readability
    • Neoadjuvant Therapy [1632], Neoadjuvant Therapy - Clinical Response [1633], and Neoadjuvant Therapy - Treatment Effects [1634] were added to all schemas
    • Derived Summary Stage 2018 [762]: Validation tables were added based on SS2018 [764] for the schema, the coding notes were not included
    • Derived Summary Grade 2018 [1975]: Validation tables were added based on Grade Clinical [3843] for the schema, the coding notes were not included
    • Version 9 Updated Diseases: AJCC released the 9th revision of the 4 diseases which will be effective for cases diagnosed 1/1/2025 or after. There are now 2 schemas for each.
      • Lung [8th: 2018-2024], Schema ID [#3800] = 00360
      • Lung [V9: 2025+], Schema ID [#3800] = 09360
      • Nasopharynx [8th: 2018-2024], Schema ID [#3800] = 00090
      • Nasopharynx [V9: 2025+], Schema ID [#3800] = 09090
      • Pleural Mesothelioma [8th: 2018-2024], Schema ID [#3800] =00370
      • Pleural Mesothelioma [V9: 2025+], Schema ID [#3800] =09370
      • Thymus [8th: 2018-2024], Schema ID [#3800] [#3800] =00350
      • Thymus [V9: 2025+], Schema ID [#3800] = 09350

  • Appendix 8th, Appendix V9

    • EOD Primary Tumor [772]: Note 6 added to clarify when to use Code 300; Code 300 modified to clarify Subserosa; Code 400 modified to clarify Mesoappendix; Code 500 modified to clarify invasion through serosa; Code 600 removed (See 'EOD v3.2 Review and Conversion'); Code 750 modified to remove reference to mucinous tumors
    • EOD Regional Nodes [774]: Note 2 added to clarify coding of nodal mets relating to LAMN; Note 3 added to describe how to use Clinical Only codes; Codes 450-700 added for Clinical assessment only
    • EOD Mets [776]: Code 30 modified to include peritoneal spread with LAMN tumors
    • Summary Stage 2018 [764]: Note 3 added to clarify coding of LAMN behavior; Note 4 added to clarify when to use Code 1 for LAMN; Code 5 modified to clarify coding of nodal mets related to LAMN; Code 0 modified to include in situ for LAMN and HAMN descriptions; Code 1 modified to provide more detail related to subserosa and LAMN; Code 2 modified to provide more detail mesoappendix; Code 7 modified to provide more detail related to LAMN

  • Bile Ducts Distal, Bile Ducts Perihilar, Cystic Duct, Gallbladder

    • EOD Regional Nodes [774]: Note 2 added to describe how to use Clinical Only codes; Codes 725, 775 added for Clinical assessment only

  • Brain 8th, Brain V9

    • EOD Primary Tumor [772]: Note 1 added to clarify coding of /0 and /1 tumors; Note 3 modified to clarify that documentation must state crossing the midline

  • Brain 8th, Brain V9, CNS Other 8th, CNS Other V9, Intracranial Gland 8th, Intracranial Gland V9

    • EOD Mets [776]: Note 1 added to clarify coding of /0 and /1 tumors; Note 2 added to define Leptomeningeal metastases
    • Summary Stage 2018 [764]: Note 5 added to clarify coding of /0 and /1 tumors

  • Brain 8th, Brain V9, CNS Other 8th, CNS Other V9

    • EOD Mets [776]: Code 70 modified to provide more examples under Metastasis within CNS and CSF pathways

  • CNS Other 8th, CNS Other V9

    • EOD Primary Tumor [772]: Note 1 added to clarify coding of /0 and /1 tumors; Note 2 added to clarify crossing the midline vs midline shift; Note 3 added to define discontiguous spread

  • Colon and Rectum

    • EOD Regional Nodes [774]: Note 3 added to describe how to use Clinical Only codes; Codes 350-600 added for Clinical assessment only

  • Esophagus

    • EOD Regional Nodes [774]: Note 3 added to describe how to use Clinical Only codes; Codes 725, 750, 775 added for Clinical assessment only

  • Intracranial Gland 8th, Intracranial Gland V9

    • EOD Primary Tumor [772]: Note 1 added to clarify coding of /0 and /1 tumors

  • Lymphoma, Lymphoma CLL/SLL

    • EOD Primary Tumor [772]: Note 8 added to define Splenic involvement; Note 14 added to describe how to use Code 800
    • Summary Stage 2018 [764]: Note 7 added to define Splenic involvement; Note 8 added to describe how to code bilateral sites

  • Medulloblastoma V9

    • EOD Primary Tumor [772]: Note 1 added to clarify coding of /0 and /1 tumors; Note 2 modified to clarify this field is for single tumors and provide guidance on coding multiple tumors; Note 3 added to clarify crossing the midline vs midline shift; Note 4 modified to clarify how to code direct or contiguous extension; Code 150 modified to specify single tumor is confined to primary site; Code 250 modified to specify single tumor confined to primary site; Code 999 modified to include multiple tumors and single tumor with extension to adjacent site
    • EOD Mets [776]: Note 1 added to clarify coding of /0 and /1 tumors; Note 4 added to clarify the coding of Leptomeningeal metastases; Code 15 modified to remove 'Microscopic confirmation' of tumor cells in CSF; Code 35 modified to include visible metastasis in spine, metastasis with CNS and CSF pathways (with examples), and to remove Gross spinal subarachnoid seeding
    • Summary Stage 2018 [764]: Note 3 modified to clarify coding of /0 and /1 tumors

  • Melanoma Skin

    • EOD Regional Nodes [774]: Note 2 added to describe when to use Code 000; Old Note 8 related to nodes for C210 and C500 removed; Renumbered Note 8 modified to include nodes for C445

  • Pancreas

    • EOD Regional Nodes [774]: Note 4 added to describe how to use Clinical Only codes; Codes 725, 775 added for Clinical assessment only

  • Prostate

    • EOD Prostate Pathologic Extension [3919]: Note 5 added to describe when to use Code 300; Note 8 added to describe when to use Code 800

  • Small Intestine

    • EOD Regional Nodes [774]: Note 4 added to describe how to use Clinical Only codes; Codes 600, 700 added for Clinical assessment only

  • Soft Tissue Abdomen and Thoracic

    • Schema Selection: Primary Site [400] = C340-C349 with Histology ICDO3 [522] = 8982 removed from this schema for 2025 and later. This combination is now found in Lung V9
    • Schema Selection: Primary Site [400] = C379 with Histology ICDO3 [522] = 8980 removed from this schema for 2025 and later. This combination is now found in Thymus V9

  • Stomach

    • EOD Regional Nodes [774]: Note 4 added to describe how to use Clinical Only codes; Codes 450-700 added for Clinical assessment only

  • Testis

    • EOD Primary Tumor [772]: Code 200 modified to remove Surface implants (surface of vaginalis tunica) and Tunica vaginalis involved; Code 300 modified to add Surface implants (surface of vaginalis tunica) and Tunica vaginalis involved;

  • Thyroid, Thyroid Medullary

    • EOD Regional Nodes [774]: Note 2 modified to include that Code 800 is to be used when only involvement is psammoma bodies only
    • Summary Stage 2018 [764]: Note 3 added to clarify how to code psammoma bodies only

SSDI and Grade - NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on https://apps.naaccr.org/ssdi/list/ for complete information.

  • General Changes

    • Documentation for all SSDIs was overhauled and restructured to prepare for new method of SSDI manual creation
      • Description/Definition, Rationale, Additional Information and Coding Guidelines were added to the SSDI
      • Some information stored in Notes in v3.1 and prior was moved to these new fields and repetitive text was removed
      • The structure of the notes have changes to that the notes have a header in bold to improve readability

  • Appendix 8th, Appendix V9

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical (yc) [1068], Grade Post Therapy Path (yp) [3845]: New Note (4 or 5) added defining how to assign grade to LAMN and HAMN tumors

  • Appendix V9

    • Histologic Subtype [3960}: internal name and tag were corrected (changed from Histology subtype)

  • Brain V9

    • Brain Primary Tumor Location [3964]: Required by all standard setters, CoC and CCCR were added
    • Brain Molecular Markers [3816]: Coding Guideline added describing when to code 86

  • Breast

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical (yc) [1068], Grade Post Therapy Path (yp) [3845]: Extensive restructuring of Notes 4, 5, 6 for Clinical and Post Therapy Clinical; Notes 5, 6, 7 for Pathological, Post Therapy Pathological

  • Buccal Mucosa, Floor of Mouth, Gum, Hypopharynx, Lip, Mouth Other, Oropharynx HPV-Mediated (p16+), Oropharynx (p16-), Palate Hard, Tongue Anterior

    • SEER Site-Specific Fact 1 [3700]: Note 5 modified to match the 2 digit codes

  • Buccal Mucosa, Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck, Cutaneous Carcinoma of Head and Neck, Floor of Mouth, Gum, Hypopharynx, Larynx Glottic, Larynx Other, Larynx Subglottic, Larynx Supraglottic, Lip, Major Salivary Glands, Maxillary Sinus, Melanoma Head and Neck, Mouth Other, Nasal Cavity and Ethmoid Sinus, Nasopharynx [8th: 018-2024], Nasopharynx [V9: 2025+], Oropharynx HPV-Mediated (p16+), Oropharynx (p16-), Palate Hard, Tongue Anterior

    • LN Size [3883]: field label in schemas was outdated and was updated to consistently be 'LN Size'

  • Cervix Sarcoma, Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical (yc) [1068], Grade Post Therapy Path (yp) [3845]: Note (3 or 4) added to describe how to capture grade for endometrioid carcinoma

  • Colon and Rectum

    • Circumferential Resection Margin [3823]: Note 5, moved to Additional information, modified to remove 'Circumferential resection margin' and add 'pericolonic resection margin'
    • BRAF Mutational Analysis [3940]: Code 3 added as 'Abnormal (mutated)/detected, KIAA1549-BRAF'

  • Esophagus, Esophagus Squamous, Stomach

    • HER2 Overall Summary [3855]: Default changed to 8 as it is not required by all standard setters

  • Lung 8th, Lung V9

    • Visceral and Parietal Pleural Invasion [3937]: Note 2 modified to specify an exception for in situ (/2) tumors

  • Lung V9

    • PD-L1 [1174]: added as a new SSDI; required by SEER for 2025 forward

  • Lymphoma, Lymphoma CLL/SLL

    • B Symptoms [3812]: Added (100.4 F) to Note 2, bullet 1 and to Code 1, 3rd line

  • Lymphoma, Lymphoma CLL/SLL, Plasma Cell Disorder, Plasma Cell Myeloma, Primary Cutaneous Lymphoma,

    • PTLD [1172]: added as a new SSDI; required by SEER for 2025 forward

  • Melanoma Choroid and Ciliary Body, Melanoma Iris

    • Chromosome 3 Status [3821]: Code 3 modified to include 'Loss of BAP1 expression'

  • Melanoma Skin

    • Clinical Margin Width [3961]: Default changed to XX.8 as it is not required by all standard setters; Note 3 modified to describe how to capture data when only a range is provided

  • Pleural Mesothelioma V9

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical (yc) [1068], Grade Post Therapy Path (yp) [3845]: new grade definitions developed for the V9 schema

  • Prostate

    • Gleason Patterns Pathological [3839], Gleason Score Pathological [3841], Gleason Tertiary Pattern [3842]: added Note 5 (7 for Gleason Patterns Pathological) detailing how to code Active Surveillance followed by Radial Prostatectomy
    • Number of Cores Examined [3897], Number of Cores Positive [3898]: Notes 2 and 3 were combined into Note 2 Priority order describing priority order and points of interest for each source

EOD Master ONLY

  • NET Appendix 8th, NET Appendix V9
    • Derived EOD 2018 T [785]: EOD Primary Tumor [772] Code 200 modified to always derive T3. This may also change the value of Derived EOD 2018 Stage Group [818] (See 'EOD v3.2 Review and Conversion')
Assets 6
Loading